Fosbretabulin for the treatment of anaplastic thyroid cancer

被引：1
|
作者：
Granata, Roberta [1 ]
Locati, Laura D. [1 ]
Licitra, Lisa [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Milan, Italy
来源：
FUTURE ONCOLOGY | 2014年 / 10卷 / 13期
关键词：
anaplastic thyroid cancer; fosbretabulin; tubulin-binding agent; COMBRETASTATIN A-4 PHOSPHATE; A4; PHOSPHATE; PHASE-II; TRIAL; AGENT; PATHOGENESIS; MANAGEMENT; CARCINOMA; SCHEDULE;
D O I：
10.2217/FON.14.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
引用
收藏
页码：2015 / 2021
页数：7
相关论文
共 50 条
  • [41] Anaplastic thyroid cancer and hyperthyroidism
    Vijay Kumar
    Bruno Blanchon
    Xin Gu
    Marjorie Fowler
    David Scarborough
    Cherie Ann Nathan
    Subhashini Yaturu
    Endocrine Pathology, 2005, 16 : 245 - 250
  • [42] Treatment of anaplastic thyroid carcinoma
    Rao, S. S.
    Haughey, B. H.
    Grigsby, P. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S416 - S416
  • [43] Anaplastic thyroid cancer: An update
    Rao, Sarika N.
    Smallridge, Robert C.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (01)
  • [44] Management of anaplastic thyroid cancer
    Keutgen, Xavier M.
    Sadowski, Samira M.
    Kebebew, Electron
    GLAND SURGERY, 2015, 4 (01) : 44 - 51
  • [45] Immunotherapy in anaplastic thyroid cancer
    Ma, Maoguang
    Lin, Bo
    Wang, Mingdian
    Liang, Xiaoli
    Su, Lei
    Okose, Okenwa
    Lv, Weiming
    Li, Jie
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (03): : 974 - 988
  • [46] Lenvatinib for Anaplastic Thyroid Cancer
    Tahara, Makoto
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Sasaki, Tatsuya
    Suzuki, Takuya
    Fujino, Katsuki
    Dutcus, Corina E.
    Takahashi, Shunji
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [47] The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer
    Mika, Justyna
    Labaj, Wojciech
    Chekan, Mykola
    Abramowicz, Agata
    Pietrowska, Monika
    Polanski, Andrzej
    Widlak, Piotr
    JOURNAL OF APPLIED GENETICS, 2021, 62 (01) : 115 - 120
  • [48] The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer
    Justyna Mika
    Wojciech Łabaj
    Mykola Chekan
    Agata Abramowicz
    Monika Pietrowska
    Andrzej Polański
    Piotr Widłak
    Journal of Applied Genetics, 2021, 62 : 115 - 120
  • [49] Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients
    Augustin, Teresa
    Oliinyk, Dmytro
    Koehler, Viktoria Florentine
    Rauch, Josefine
    Belka, Claus
    Spitzweg, Christine
    Kasmann, Lukas
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 29
  • [50] Treatment and Survival Vary by Race/Ethnicity in Patients With Anaplastic Thyroid Cancer
    Roche, Ansley M.
    Fedewa, Stacey A.
    Shi, Lucy L.
    Chen, Amy Y.
    CANCER, 2018, 124 (08) : 1780 - 1790
12345